Vision care startup Neurolens announces completion of a $67 million financing.
The investment will fuel continued product innovation and growth initiatives.
Neurolens are the first prescription lenses that go beyond visual acuity to provide comfort for those who complain of headaches, neck/shoulder pain, and eyestrain. Its lens can detect eye misalignment as small as 0.01 Prism Diopters and collects over 10,000 data points per patient.
Earlier in August, Neurolens released a parallel arm study results evaluating reading speed at baseline. The study revealed that after seven days of lens wear, the average improvement in reading speed with Neurolenses was almost 70% higher than the improvement seen with other premium lens designs.
“While we have grown tenfold in the past three years, the unmet patient need remains massive,” said Pierre Bertrand, Neurolens CEO. “Nearly 6 out of 10 Americans are reporting daily symptoms of Digital Vision Syndrome, and we are excited to continue bringing solutions to independent optometry to meet their needs. We are grateful to see both current and new investors embrace our mission to transform eye care beyond visual acuity.”...